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Like other cancers, most gynecologic cancers are caused by aberrant expression of cancer-
related genes. Epigenetics is one of the most important gene expression mechanisms,
which contribute to cancer development and progression by regulating cancer-related
genes. Since the discovery of differential gene expression patterns in cancer cells when
compared with normal cells, extensive efforts have been made to explore the origins of
abnormal gene expression in cancer. Epigenetics, the study of inheritable changes in gene
expression that do not alter DNA sequence is a key area of this research. DNA methyla-
tion and histone modification are well-known epigenetic mechanisms, while microRNAs
and alternative splicing have recently been identified as important regulators of epige-
netic mechanisms. These mechanisms not only affect specific target gene expression but
also regulate the functioning of other epigenetic mechanisms. Moreover, these diverse
epigenetic regulations occur simultaneously. Epigenetic regulation of gene expression
is extraordinarily complicated and all epigenetic mechanisms to be studied at once to
determine the exact gene regulation mechanisms. Traditionally, the contribution of epige-
netics to cancer is thought to be mediated through the inactivation of tumor suppressor
genes expression. But recently, it is arising that some oncogenes or cancer-promoting
genes (CPGs) are overexpressed in diverse type of cancers through epigenetic dere-
pression mechanism, such as DNA and histone demethylation. Epigenetic derepression
arises from diverse epigenetic changes, and all of these mechanisms actively interact
with each other to increase oncogenes or CPGs expression in cancer cell. Oncogenes or
CPGs overexpressed through epigenetic derepression can initiate cancer development,
and accumulation of these abnormal epigenetic changes makes cancer more aggressive
and treatment resistance. This review discusses epigenetic mechanisms involved in the
overexpression of oncogenes or CPGs via epigenetic derepression in gynecologic can-
cers.Therefore, improved understanding of these epigenetic mechanisms will provide new
targets for gynecologic cancer treatment.
Keywords: epigenetic derepression, gynecologic cancer, DNA methylation, histone modification, microRNA,
epigenetic therapy
INTRODUCTION
Cancer is a heterogeneous disease caused by uncontrollable cell
division (1). Early research recognized cancer as a genetic dis-
order of proliferation-related genes, but recent studies have
approached cancer multidirectionally, examining resistance to cell
death, angiogenesis, invasion, metastasis, and other properties (2).
Many genes related to these properties can be roughly divided
into two groups: tumor suppressor genes (TSGs) and oncogenes
or cancer-promoting genes (CPGs) (3, 4). As the name implies,
TSGs have cancer inhibitory roles, and their functions are lost
in cancer cells. Conversely, oncogenes or CPGs have the poten-
tial to cause cancer, and they are overexpressed in many cancers.
Both TSGs and oncogenes or CPGs are abnormally expressed
in diverse cancers via various mechanisms, and each gene has
a specific function according to the characteristics of specific
cancers. Cancer develops from both genetic and epigenetic muta-
tions (5), and progression is more severe when such mutations
accumulate, interrupting the normal function of cancer-related
genes and inducing resistance to chemotherapy that makes can-
cer treatment more difficult. Such mutations may be inherited
from parents or acquired during life as a result of diverse envi-
ronmental factors such as chemical and hormone exposure, diet,
alcohol use, smoking, and inflammation (6–8). Epigenetics is the
key mediator connecting environmental factors to gene regulation
systems (9–11). Moreover, a cohort study of twins in Europe has
revealed that environmental factors are major causes of cancer,
and inherited genetic factors are minor contributors (8). There-
fore, the major driving force of cancer development is clearly
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acquired mutations or epigenetic alterations caused by environ-
mental factors rather than inherited genetic mutations. So far,
many research results have revealed a significant role of epigenetic
regulation in gynecologic cancer. Aberrant gene expression caused
by epigenetic mechanisms is mediated in two main ways. One is
epigenetic silencing of TSGs, and the other is epigenetic dere-
pression of oncogenes or CPGs (12). Some recent studies have
shown that oncogenes or CPGs are overexpressed in human can-
cers through epigenetic derepression mechanisms, suggesting a
significant role for these mechanisms in human cancers (13–16).
Moreover, these mechanisms are tightly connected to one another,
so it is important that integrated analysis of genetic/epigenetic
mechanisms at the same time. Many researchers are trying to iden-
tify the significant epigenetic derepression mechanisms underlying
the development of gynecologic cancers. This review article will
discuss the diverse epigenetic derepression mechanisms related to
aberrant gene expression in gynecologic cancer and their potency
as targets for gynecologic cancer therapy.
GYNECOLOGIC CANCER
Gynecologic cancer includes any cancer that occurs in the female
reproductive organs. There are five frequently occurring gyne-
cologic cancers: ovarian, cervical, endometrial (uterine), vaginal,
and vulvar. Gynecologic cancers usually have high mortality rates,
because it is difficult to detect the cancer in early stage (17).
Therefore, convenient diagnostic strategies for early detection of
gynecologic cancers are needed. Human papillomavirus (HPV)
is the major cause of most of these cancers. Especially, HPV-16
and HPV-18 cause approximately 70% of cervical cancers (18),
reflecting the severe carcinogenic properties of these HPV types.
Ovarian cancer is classified into three major types according
to the histology of the tumor. Epithelial ovarian cancer is the
predominant type, and the other types, sex cord stromal tumors
and germ cell tumors, account for <10% of malignant ovarian
cancers (19). Among epithelial ovarian cancers, 80% are serous
adenocarcinoma and the remainder are mucinous, endometrioid,
or clear cell carcinoma (20). Epithelial ovarian cancer is gener-
ally believed to originate in the ovarian epithelium, but a new
hypothesis that high-grade serous ovarian cancer (HGS-OvCa)
originates in the fimbrial cells of fallopian tubes rather than the
ovarian epithelium has recently arisen (21). Mutation of breast
cancer 1 and 2, early onset (BRCA1 and BRCA2) are known to
influence ovarian cancer development (22) and can be used as
diagnostic or prognostic factors (23). Recently, the cancer genome
atlas (TCGA) project has also found that approximately 10% of
HGS-OvCa patients have BRCA1/2 germline mutations. In addi-
tion, nearly all HGS-OvCa samples show TP53 mutation (24).
Serum cancer antigen 125 level also has significant correlation with
tumor stage, grade, and histologic type, making it a useful prog-
nostic factor in epithelial ovarian cancer (25, 26). It is also a widely
used monitoring tool for assessing the effectiveness of therapy
and asymptomatic recurrence rates at follow-up (27). Other type
of cancers also show abnormal genetic/epigenetic status. Some
genes are abnormally regulated by epigenetic mechanisms in cer-
vical cancer (28–30), suggesting that epigenetics may be important
in cervical cancer carcinogenesis. In case of endometrioid can-
cer, genetic mutations of KRAS, phosphate and tensin homolog
(PTEN ), and beta-catenin (CTNNB1) are associated with the ini-
tiation of endometrioid carcinomas (31). Moreover, endometrial
cancer also displays genetic mutations of diverse TSGs including
TP53, CTNNB1, phosphatidylinositol-4,5-bisphosphate 3-kinase,
catalytic subunit alpha (PIK3CA),PTEN, and protein phosphatase
2 and regulatory subunit A alpha (PPP2R1A) (32–34). Vaginal can-
cer and vulvar cancer are relatively rare gynecologic cancer (35),
so the genetic/epigenetic mutations are not studied well.
CANCER EPIGENETICS
Epigenetics refers to the study of inheritable alterations in gene
expression without accompanying changes in genomic DNA
sequence, and it explains variations in gene expression originat-
ing from the same genetic information (36). Among the various
factors related to cancer initiation and development, epigenetic
alteration is critical because it causes global aberrant gene expres-
sion (37). More than 300 genes related to cancer cell properties
are epigenetically deregulated in various human cancers including
those of breast, gastric, ovarian, and prostate (38, 39). This num-
ber is expected to increase rapidly as epigenetic studies of cancer
continue and techniques advance.
DNA METHYLATION IN CANCER
The best-known epigenetic mechanism is DNA methylation,
which usually represses downstream gene expression by changing
local chromatin structure (40–42). Human tumors were initially
discovered to have global DNA hypomethylation and local DNA
hypermethylation patterns (43), and since then, many researchers
have undertaken studies of the relationship between DNA methy-
lation and cancer. As normal cells progress to invasive cancer
cells, their overall DNA methylation levels decrease, whereas CpG
Island hypermethylation and alteration of histone modification
patterns accumulate gradually (36). TSG inactivation by promoter
regions hypermethylation or DNA hypomethylation of highly
repeated DNA regions are found in diverse cancer types. In addi-
tion, DNA hypomethylation in promoter regions has recently been
discovered to derepress some CPGs or proto-oncogenes that are
repressed in normal cells (12). Tahiliani et al. (44) have recently
shown that tet methylcytosine dioxygenase (TET) 1 can convert 5-
methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC) in
a 2-oxoglutarate- and Fe (II)-dependent manner. 5-hmC is then
actively demethylated via additional mechanisms including gly-
cosylation and base excision repair. DNA demethylation of CpG
Islands in promoter regions can reactivate downstream genes.
Some genes repressed by DNA hypermethylation can be dere-
pressed through DNA demethylation, and the latter plays a critical
role in gene expression mechanisms in stem cell differentiation
(45) or neural memory and immune systems (46). Among these
properties, the pluripotency of stem cells is closely related to TET
proteins by NANOG-dependent manner (47, 48). TET proteins
also associated with diverse type of cancers. In breast cancer, TET1
demethylates the promoter region of homeobox A (HOXA) genes
to induce the expression of HOXA7, 9, resulting tumor growth
and metastasis suppression (49). In case of hepatocellular car-
cinoma, it is suggested that 5-hmC may be used as prognostic
marker and decreased TET1 is underlying mechanism of 5-hmC
loss (50).
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HISTONE MODIFICATION IN CANCER
Histone modification is also major epigenetic mechanisms. Each
histone modification can affect the overall structure of chromatin,
and therefore it can also affect gene expression by changing the
condensation of DNA or recruiting effector molecules that control
downstream gene expression. However, unlike DNA methylation,
histone modification is directly associated with both gene activa-
tion and gene repression according to individual modifications or
specific modified genomic regions (51). Moreover, histone mod-
ification can positively or negatively affect other modifications
by cross-interactions (52). Aberrant histone modification causes
abnormal expression of cancer-related genes by changing DNA
structure. Cancer cells are characterized by the loss of active his-
tone marks in the promoter regions of TSGs or loss of repressive
marks in subtelomeric DNA and other DNA repeats, which make
the chromatin structure more flexible (53).
MicroRNA AND ALTERNATIVE SPLICING IN CANCER
Gene expression also can be regulated at the post-transcriptional
level by microRNA (miRNA). miRNA is a small non-coding RNA
that is normally composed of 20–22 nucleotides. Most miRNAs
inhibit the translation of mRNA to protein by binding to the
3′-untranslated region of target mRNAs through imperfect com-
plementary binding. More than 1400 miRNAs related to almost
every cellular function, including proliferation, differentiation,
and development, have been identified in humans (54–56). Proper
miRNA regulation is also broken in cancers. Many factors affect
miRNA biogenesis, including miRNA genomic localization, tran-
scriptional regulation, processing steps, and post-transcriptional
modification (57). Abnormal control of these steps causes over-
all miRNA dysregulation, which leads to aberrant cancer-related
genes expression at post-transcription level. For example, miR-21
and miR-17-92 clusters are representative “oncomiRs” and their
expression is enriched in various cancers (58, 59). Conversely,
tumor suppressor miRNAs (TSmiRNAs) have also been found.
The let-7/miR-98 families play roles in both apoptosis and cell pro-
liferation pathways (60), and the miR-141/200 families are highly
associated with epithelial-to-mesenchymal transition (EMT) or
chemosensitivity (61, 62). It is now clear that alternative splicing
is an important gene expression mechanism and emerging evi-
dence indicates that alternative splicing regulates not only splicing
machinery, but also chromatin structure and cancer development
(63–65). Serine/arginine-rich splicing factor 1 (SRSF1) is a typical
alternative splicing regulator that shows proto-oncogenic prop-
erties. The overexpression of SRSF1 transforms fibroblasts into
sarcomas (66) and makes mammary epithelial cells more anti-
apoptotic by regulating BIM and BIN1 splicing isoforms (67).
Interestingly, some genes including Wilms tumor suppressor gene
(WT1) (68) and Bcl-x (69, 70) have both properties of oncogene
or tumor suppressor gene according to their splicing isoform.
MUTUAL INTERACTION AMONG EPIGENETIC MECHANISMS IN
CANCER
All of these epigenetic mechanisms are tightly connected to one
another and compose the overall gene regulation system. There-
fore, integrated analysis of diverse epigenetic mechanisms is essen-
tial to understanding the gene expression regulation system in
its entirety. The miR-29 family, including miR-29a, miR-29b, and
miR-29c, is representative miRNA that interacts with other epige-
netic mechanisms. The expression of miR-29b is regulated by both
histone modification (71) and DNA methylation (72). On the con-
trary, recent studies have shown that miR-29a is closely correlated
with DNMT proteins, suggesting that the miR-29 family has an
important role in overall epigenetic mechanisms (73–75). miR-
7/miR-218 can modify DNA methylation and histone modifica-
tion status by decreasing homeobox B3 (HOXB3) expression (76),
and miR-28/miR-505 can affect alternative splicing through SRSF1
inhibition (77). With these recent findings, integrated analysis of
epigenetic studies has gradually progressed through the efforts of
diverse groups. TCGA is a substantial cooperative project inves-
tigating genome-wide epigenetic alterations in various cancers.
Creighton et al. (78) have profiled miRNA expression in 489 high-
grade serous ovarian adenocarcinomas in the TCGA database and
analyzed their widespread effects on gene expression. The results
show a reverse correlation between miRNA and mRNA level that
corresponds with canonical interaction of miRNA and mRNA.
Integrated analysis of gene amplification and gene expression (79);
gene expression, DNA methylation, and miRNA expression (80);
DNA copy number, DNA methylation, and mRNA expression (81)
have also been performed recently. These studies demonstrate
the importance of integrating diverse types of epigenetic data to
understand cancer biology more thoroughly.
INTEGRATED EPIGENETIC DEREPRESSION MECHANISMS IN
CANCER
Until recently, the focus of cancer epigenetics has been the repres-
sion of TSG expression, and many reports have discussed the
repression by DNA hypermethylation or decreases in active histone
marks in promoter regions. The concept of epigenetic derepression
mechanisms in cancer was first introduced by Feinberg and Vogel-
stein in 1983 (43). They found that the promoter regions of two
human growth hormone γ-globin genes are methylated in normal
tissues but hypomethylated in malignant colon cancers overex-
pressing both genes. Since then, many studies have found that a
number of oncogenes or CPGs are abnormally increased in sev-
eral cancers by epigenetic derepression. These genes are involved
in critical functions in cancer cells including proliferation, DNA
repair, angiogenesis, cell migration, metastasis, and chemoresis-
tance (82). Therefore,determination of the molecular mechanisms
underlying the overexpression of oncogenes or CPGs is necessary
in the study of cancer, and epigenetic derepression may be a key
mechanism.
The inactivation of TSGs is mediated through TSG pro-
moter region DNA hypermethylation and repressive histone
modification including H2A ubiquitination (83), H3K9me2,
H3K9me3, H3K27me2, H3K27me3 (84, 85), and H4K20me3
(86), resulting in low TSG expression. Moreover, aberrant over-
expression of oncomiRs, which is caused by DNA hypomethy-
lation and active histone modification including H2Bub
(83), H3K4me1, H3K4me2, H3K4me3 (87, 88), H3K79me1,
H3K79me2, H3K79me3 (84, 89), H3Ac, and H4Ac (90) degrades
TSG mRNAs or inhibits translation of mRNA, increasing
TSG repression. Conversely, the activation of CPGs via DNA
hypomethylation and active histone modification facilitates the
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transcription of these genes. Furthermore, DNA hypermethyla-
tion and repressive histone modification of TSmiRNA gene pro-
moters reduce expression, derepressing CPGs normally repressed
by TSmiRNAs. These diverse epigenetic changes occur through-
out the genome at the same moment, resulting in the overex-
pression of oncogenes or CPGs and downregulation of TSGs.
Ultimately, the sum of these epigenetic aberrations contributes
to cancer development, progression, and treatment resistance
(Figure 1).
These epigenetic mechanisms work not only in gene pro-
moter regions but also in non-promoter regions, which are highly
repeated DNA sequence regions. Specifically, highly repeated
regions occupy nearly half of the genome, and these regions are
silenced by DNA hypermethylation to maintain DNA integrity
and stability (91). Decreases in DNA methylation in these repeated
regions induce genomic alteration, resulting in the genome-wide
instability usually observed in cancers (Figure 2) (92). For
example,LINE-1 repeat is a representative repeated sequence in the
human genome that is usually hypomethylated in various cancers
(93–95). Moreover, LINE-1 hypomethylation is related to poor
prognosis in various cancers including HCC (96), gastric cancer
(97), and multiple myeloma (98).
EPIGENETIC DEREPRESSION IN GYNECOLOGIC CANCER
In gynecologic cancer, Chan et al. (99) initially showed thatBRCA2
expression is increased in ovarian cancer via promoter region DNA
hypomethylation. Since the publication of these studies, a number
of groups have investigated epigenetic derepression mechanisms
in various gynecologic cancers (Table 1). Our group also have
recently demonstrated that the CPGs CLDN3 and CLDN4 are
overexpressed in ovarian cancer in association with decreases in
repressive histone marks (13).
FIGURE 1 | Epigenetic derepression mechanisms in cancer.
(A) Oncogenes or cancer-promoting genes (CPGs), are overexpressed
through DNA hypomethylation or gain of active histone modification such as
histone 2B ubiquitination, mono-, di-, tri-methylation of the fourth lysine in the
histone 3 tail (H3K4me1, H3K4me2, and H3K4me3), mono-, di-,
tri-methylation of the 79th lysine in the histone 3 tail (H3K79me1, H3K79me2,
and H3K79me3), histone 3 acetylation (H3Ac), and histone 4 acetylation
(H4Ac) in the promoter region of the gene. Oncogene or CPG expression can
be increased through suppression of tumor suppressor micro RNAs
(TSmiRNAs).TSmiRNAs, which degrade the messenger RNA of the oncogene
or CPG, are repressed through epigenetic mechanisms such as DNA
hypermethylation and gain of repressive histone tri-methylation of histone 2A
ubiquitination, di-, tri-methylation of the 9th lysine in the histone 3 tail
(H3K9me2 and H3K9me3), di-tri-methylation of the 27th lysine in the histone
3 tail (H3K27me2 and H3K27me3), and tri-methylation of the 20th lysine in the
histone 4 tail (H4K20me3). (B) Tumor-suppressor genes (TSGs) are abnormally
downregulated in cancer via gain of repressive epigenetic markers. In
addition, TSGs are inactivated by oncomiRs, which degrade TSGs. Ultimately,
increased oncogene or CPGs and decreased TSGs expression contribute to
cancer development, cancer progression, and resistance to cancer therapy.
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FIGURE 2 | DNA hypomethylation in a highly repeated DNA sequence
region. Highly repeated sequence regions are mainly categorized as tandem
repeats and interspersed repeats. These regions are highly methylated in
normal cells to maintain genomic integrity, and hypomethylation of the
regions increases genetic alterations and genomic instability, resulting cancer
development.
EPIGENETIC DEREPRESSION IN OVARIAN CANCER
Candidate oncogene synuclein γ (SNCG) is known to stimulate
cell proliferation and metastasis in several cancers. Gupta et al.
(107) have shown that SNCG is overexpressed in ovarian can-
cer cells through hypomethylation of the CpG Island located in
exon 1. Furthermore, SNCG expression is restored in some cell
lines with low endogenous SNCG expression levels through treat-
ment with the DNA demethylating agent 5-aza-CdR, supporting
the tumorigenic role of DNA hypomethylation in ovarian cancer.
Homeobox A 10 (HOXA10) is also regulated by DNA methylation
in ovarian cancer. HOXA10 has crucial functions in receptivity,
embryo implantation, and decidualization. It is overexpressed in
ovarian cancers, and its gene promoter regions are hypomethy-
lated, which may be a potential prognostic factor in the disease
(105). DNA hypomethylation also contributes to chemoresistance
in gynecologic cancer. The myelin and lymphocyte protein gene
(MAL) is among the most highly expressed genes in ovarian cancer.
Its expression is also regulated by promoter region DNA methy-
lation, and it is largely demethylated in primary ovarian cancer
tissues and ovarian cancer cell lines (106). In a study by Lee et al.
(106), MAL expression patterns showed significant reverse corre-
lation with platinum resistance, and the DNA methylation status
of the MAL promoter region can be used as a marker for platinum
drug sensitivity and as a therapeutic target in ovarian cancer.
Other studies have demonstrated integrated mechanisms of
DNA methylation and histone modification related to epigenetic
derepression in ovarian cancer. CLDN3 and CLDN4, which are
separated by only 60 kb on chromosome 7, are transcribed in
opposite directions and highly overexpressed in ovarian cancer.
These tight junction proteins reportedly promote the migration
and invasion of ovarian epithelial cells (121), and abnormal over-
expression of CLDN3 and CLDN4 is caused by the simultaneous
action of DNA methylation and histone modification. For exam-
ple, Honda et al. (103, 104) have reported that DNA demethylation
and increased H3 acetylation at the Sp1 binding site are critical
factors in the overexpression of CLDN3 and CLDN4 (103, 104).
Kwon et al. (13) have also shown the importance of simultaneous
epigenetic changes in CLDN3 and CLDN4 overexpression. They
have found that CLDN3 and CLDN4 repression in normal ovar-
ian cells is associated with “bivalent” histone modification, and
simultaneous increase in H3K4me3 and decrease in H4K20me3
and H3K27me3 work together to induce CLDN3 and CLDN4
expression levels (13). Interestingly, DNA methylation is inversely
correlated only with the expression of CLDN4, not with CLDN3
expression. The region analyzed in this study contained Sp1 bind-
ing sites, but the cell lines are completely different. Therefore,
the individual characteristics of each cell line may be responsi-
ble for this difference. With regard to chemoresistance, tubulin,
beta 3 class III (TUBB3) overexpression has been reported as a
primary mechanism of taxane drug resistance in diverse cancers.
Epigenetic study of 66 primary ovarian tumors and 3 ovarian can-
cer cell lines has revealed that DNA methylation and chromatin
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Table 1 | Genes or miRNAs aberrantly regulated via epigenetic derepression mechanisms in gynecologic cancer.
Expression
change
Epigenetic regulation Cancer type Functions Reference
GENES
BRCA2 Overexpression DNA hypomethylation Ovarian cancer Platinum drug resistance (99, 100)
BMP2, 3, 4, 7 Overexpression DNA hypomethylation Endometrial
cancer
Cell growth and EMT (101)
CAGE Overexpression DNA hypomethylation Cervical cancer – (102)
CLDN3 and CLDN4 Overexpression DNA hypomethylation, H3
acetylation
Ovarian cancer Migration and invasion (103, 104)
CLDN3 Overexpression Loss of repressive histone
modifications
Ovarian cancer – (13)
CLDN4 Overexpression DNA hypomethylation, loss of
repressive histone modifications
Ovarian cancer – (13)
HOXA10 Overexpression DNA hypomethylation Ovarian cancer Potential prognostic cancer (105)
MAL Overexpression DNA hypomethylation Ovarian cancer Platinum drug resistance (106)
SNCG Overexpression DNA hypomethylation Ovarian cancer Cell proliferation (107)
TUBB3 Overexpression DNA hypomethylation, chromatin
acetylation
Ovarian cancer Taxane drug resistance (108)
ARID3B Overexpression miR-125a downregulation via
EGFR signaling
Ovarian cancer Epithelial-to-mesenchymal
transition
(109)
BCL3 Overexpression miR-125b downregulation Ovarian cancer Cell proliferation,
tumorigenesis
(110)
BMI1 Overexpression miR-15a and miR-16
downregulation
Ovarian cancer Correlation with histologic
grade
(111)
MAP2K3 and MAPK8 Overexpression miR-214 downregulation Cervical cancer Cell proliferation (112)
NFKB1 Overexpression miR-9 downregulation Ovarian cancer Cell proliferation (113)
PTGS2 Overexpression miR-101 downregulation Cervical cancer Cell proliferation,
migration, invasion
(114)
SERPINH1 Overexpression miR-29a downregulation Cervical cancer Metastasis (115)
VEGFA Overexpression miR-203 downregulation by DNA
hypermethylation
Cervical cancer Tumor growth,
angiogenesis
(116)
SOX4 Overexpression miR-129-2 downregulation by
DNA hypermethylation
Endometrial
cancer
Prognosis (117)
miRNAs
let-7i Downregulation – Ovarian cancer Prognosis,
chemoresistance
(118)
miR-149, miR-203, and mIR-375 Downregulation DNA hypermethylation Cervical cancer – (119)
miR-26a, miR-143, miR-145,
miR-99a, miR-203, miR-513,
miR-29a, and miR-199a
Downregulation – Cervical cancer – (120)
ARID3B, AT-rich interactive domain 3B; BCL3, B-cell chronic lymphocytic leukemia/lymphoma; BMI1, BMI1 polycomb ring finger oncogene; BMP2, 3, 4, 7, bone
morphogenetic protein 2, 3, 4, 7; BRCA2, breast cancer 2, early onset; CAGE, cancer-associated gene; CLDN3, claudin3; CLDN4, claudin4; HOXA10, homeobox A
10; MAL, myelin and lymphocyte protein gene; MAP2K3, Mitogen-activated protein kinase kinase 3; MAPK8, Mitogen-activated protein kinase 8; miRNA, microRNA;
NFKB1, nuclear factor kappa B1; PTGS2, prostaglandin-endoperoxide synthase 2; SERPINH1, serpin peptidase inhibitor, clade H (heatshock protein 47), member 1;
SOX4, SRY-box 4; SNCG, synuclein γ; TUBB3, tubulin, beta 3 class III; VEGFA, vascular endothelial growth factor A.
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acetylation are partly associated with TUBB3 overexpression in
ovarian cancer (108).
Similar to TSGs, some TSmiRNAs are also downregulated in
ovarian cancers. The let-7 miRNA family, which was the first
reported group of TSmiRNAs in cancer, represses a number
of oncogenic proteins such as KRAS, high mobility group AT-
hook 2 (HMGA2), and v-myc myelocytomatosis viral oncogene
homolog (MYC). Yang et al. (118) have identified chemotherapy
response-related miRNAs in ovarian cancer using miRNA expres-
sion microarray. Among them, let-7i expression level is signifi-
cantly reduced in chemotherapy-resistant patients, and decreased
let-7i expression is associated with shorter progression-free sur-
vival in late-stage ovarian cancer patients. Therefore, let-7i has a
tumor suppressive function related to resistance to chemotherapy,
and target genes of let-7i may be related to chemoresistance.
A common role of miRNAs is the repression of target gene
expression at the post-transcription level. Therefore, aberrantly
decreased miRNA expression enhances the expression of many tar-
get genes, some of which may contribute to cancer development in
diverse ways. EMT usually occurs during embryonic development
and contributes to tumor migration, invasion, and metastasis in
cancer. Dahl et al. (109) have shown that aberrantly low expres-
sion of miR-125a in ovarian cancer is caused by epidermal growth
factor receptor signaling, which leads to EMT through increased
levels of AT-rich interactive domain 3B (ARID3B) expression.
These results demonstrate that miRNAs may be critical media-
tors in sequential regulatory systems from signaling pathways to
cancer phenotypes. Another miR-125 family member, miR-125b,
also has tumor suppressive functions in ovarian cancer. Guan et al.
(110) have found that the expression of miR-125b is decreased in
ovarian cancer, causing overexpression of proto-oncogene B-cell
chronic lymphocytic leukemia/lymphoma (BCL3), which regu-
lates cell proliferation and tumorigenesis. In addition, the major
transcription factors nuclear factor kappa B1 and BMI1 polycomb
ring finger oncogene (BMI1) are overexpressed in ovarian cancer
through aberrant downregulation of miR-9, miR-15a, and miR-
16. Both miR-125 members contribute to cancer development by
stimulating cell proliferation in specific ways (111, 113).
EPIGENETIC DEREPRESSION IN CERVICAL CANCER
In cervical cancer, cancer-associated gene (CAGE) shows
hypomethylated patterns in its promoter region (102). Specifi-
cally, the promoter region of CAGE is frequently hypomethylated
in diverse types of cancer including breast, lung, and stomach can-
cers. A study by Lee et al. (102), which examined tissues samples
from normal patients and more than 40 cervical cancer patients,
demonstrated the significantly high correlation between CAGE
promoter hypomethylation and cervical cancer and suggested that
the DNA methylation pattern in the CAGE gene may have diag-
nostic utility. Prostaglandin-endoperoxide synthase 2 (PTGS2)
expression is also epigenetically derepressed in cervical cancer by
loss of miR-101 expression. Exogenous overexpression of miR-101
decrease cell proliferation, migration, and invasion via inhibition
of PTGS2 expression (114). Similarly to this, many recent stud-
ies find that epigenetic derepression of oncogenes or CPGs by
miRNA downregulation in cervical cancer. Mitogen-activated pro-
tein kinase kinase 3 (MAP2K3), mitogen-activated protein kinase
8 (MAPK8) and miR-214 (112), Serpin peptidase inhibitor, clade
H (heatshock protein 47), member 1 (SERPINH1) and miR-29a
(115), vascular endothelial growth factor A (VEGFA), and miR-203
(116) and so on.
As with protein-coding genes, the expression of miRNA is also
regulated by DNA methylation. Wilting et al. (119) have reported
that miR-149, miR-203, and miR-375 are located within hyper-
methylated CpG Islands with decreased miRNA expression in
cervical cancer, indicating that hypermethylated miRNAs may be
candidate markers in the detection of cancerous lesions. More-
over, a recent studies has found a panel of six miRNAs, which are
aberrantly repressed by DNA hypermethylation (122), and eight
miRNAs that show decreased expression levels in atypical dyspla-
sia and cervical cancer compared with those in normal cervix cells
(120), suggesting a significant regulatory role for miRNA in cancer
development.
EPIGENETIC CHANGES IN ENDOMETRIAL, VAGINAL, AND VULVAR
CANCER
Gynecologic cancers other than ovarian and cervical cancer have
not been researched as thoroughly, but some studies have reported
results related to epigenetic derepression mechanisms in these
cancers as well. Bone morphogenetic protein (BMP) family con-
tributes to aggressive growth and EMT, and it’s expression is
induced by promoter DNA hypomethylation in endometrial can-
cer (101). SRY-box 4 (SOX4) is often overexpressed in diverse
cancers, including prostate, liver, lung, and bladder cancer, with
poor prognostic features (123–126). In endometrial cancer, SOX4
expression is upregulated through silencing of miR-129-2, which is
mediated by DNA hypermethylation of miR-129-2 (117). Huang
et al. (117) have found that aberrant SOX4 expression is correlated
with shorter patient survival time and is also related to microsatel-
lite instability and the repression of mutL homolog 1 (MLH1) via
DNA hypermethylation, suggesting that miR-129-2 contributes to
endometrial cancer by deactivating DNA repair systems.
No direct evidence of epigenetic derepression mechanisms
have been reported in vulvar cancer, but Samartzis et al. (127)
have recently reported the differences in class I HDAC expres-
sion patterns between VIN and vulvar squamous cell cancer
(VSCC). Using tissue microarray, they discovered that class I
HDACs are highly expressed in VIN and VSCC, but HDAC2
expression in VIN is higher than that in VSCC, and HDAC3 is
more frequently expressed in VSCC. Therefore, class I HDACs
appear to stimulate vulvar cancer, suggesting specific roles for
HDAC2 and HDAC3 during cancer progression. These results
showed no clear epigenetic derepression mechanisms but provide
clues about the epigenetic regulatory role of histone acetylation
changes in vulvar cancer through analysis of HDAC expression
patterns.
DIAGNOSTIC AND PROGNOSTIC UTILITY OF EPIGENETIC
ALTERATIONS IN GYNECOLOGIC CANCER
As mentioned above, abnormal gene expression in cancer is mainly
caused by epigenetic mechanisms that contribute to cancer devel-
opment. Therefore, knowledge of underlying epigenetic mech-
anisms can be used to identify prognostic markers or develop
therapeutic targets of epigenetic drugs or small interfering RNA
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therapies. Many studies have reported the potential usefulness of
epigenetic changes in the diagnosis and prognosis of gynecologic
cancers (Table 2).
EPIGENETIC ALTERATIONS IN GYNECOLOGIC CANCER DIAGNOSIS
The most effective way to cure cancer is to detect it at its earli-
est stages and remove tumors completely before extensive cancer
development. Therefore, accurate diagnostic methods are essential
in cancer therapy. Clearly, the epigenetic status of cancer cells dif-
fers significantly from that of their normal cell counterparts, and
some of these differences can be used as diagnostic factors in spe-
cific types of cancer. Feng et al. (128) have found that genes such
as death-associated protein kinase 1 (DAPK1), retinoic acid recep-
tor beta (RARB), and twist basic helix–loop–helix transcription
factor 1 (TWIST1) might be useful markers in cervical intraep-
ithelial neoplasia and invasive cervical cancer. DNA methylation
patterns in the promoter regions of this three-gene panel efficiently
distinguished cervical intraepithelial neoplasia from invasive cer-
vical cancer, showing high specificity and sensitivity in exfoliated
cell samples from cervical cancer patients. Lai et al. (131) have also
identified six genes – SRY-box 1 (SOX1), paired box 1 (PAX1), LIM
homeobox transcription factor 1 alpha (LMX1A), NK6 home-
obox 1 (NKX6-1), Wilms tumor 1 (WT1), and one cut homeobox
1 (ONECUT1) – that show DNA hypermethylation in cervical
cancer. Fiegl et al. (132) have developed a new strategy for the
detection of endometrial cancer in cervicovaginal secretions by
examining the expression of five genes – RASSF1A, MLH1, cad-
herin 13 (CDH13), heat shock 70 kDa protein 2 (HSPA2), and
suppressor of cytokine signaling 2 (SOCS2). All endometrial can-
cer patient samples used in their study showed three or more
hypermethylated genes among the five analyzed, and 99 of 109
non-endometrial cancer samples displayed no or fewer than three
genes with DNA methylation.
EPIGENETIC ALTERATIONS IN GYNECOLOGIC CANCER PROGNOSIS
Epigenetic changes in cancer also provide prognostic informa-
tion. In ovarian cancer, reduced expression of the methylation-
controlled DNAJ gene (MCJ ) owing to DNA hypermethylation
increases chemotherapeutic drug resistance (134, 135). Interest-
ingly, the CpG Island in exon 1 ofMCJ is more critical than the pro-
moter region CpG Island for gene repression. Moreover, high levels
of DNA methylation in this region are significantly correlated with
poor response to chemotherapy and worse prognosis. These results
suggest that DNA hypermethylation in the exon region of MCJ
may be a good marker for chemoresistance in ovarian cancer. Stem
cell polycomb group targets show high DNA methylation level in
cancers. DNA methylation of the polycomb group target home-
obox A 11 (HOXA11) promoter is also increased in ovarian cancer
specimens and strongly associated with poor prognosis, making
it a potential prognostic biomarker in ovarian cancer (136). It is
well-known that HPV, which is the major cause of cervical can-
cer, genomes DNA methylation increases with cancer progression.
Very recent study suggests that combination of HPV L2/L1 and
cellular DAPK1 DNA methylation can be used as prognostic bio-
marker in cervical cancer (129). Furthermore, DNA methylation
of HPV L1/L2 nucleotide positions 5600 and 5609 highly cor-
relates with cervical cancer grade (130), supporting prognostic
function of HPV DNA methylation. Many TSGs in vulvar cancer,
including tumor protein p73 (TP73), immunoglobulin superfam-
ily member 4 (IGSf4), DAPK1, RASSF1A, RASSF2A, CDKN2A,
Table 2 | Sensitivities and specificities of epigenetic changes for diagnosis and prognosis in gynecological cancer.
Cancer Sensitivity (%) Specificity (%) Reference
GENE
DAPK1, RARB, and TWIST1 Cervical cancer 74 (For ICC) 52 (For CIN-3/CIS) 95 (For CIN-1 or less) (128)
HPV L2/L1 Cervical cancer 89 (For ICC) 80 (For HSIL/cancer) 84 (For ICC) 89 (For HSIL/cancer) (129)
DAPK1 89 (For ICC) 59 (For HSIL/cancer) 76 (For ICC) 82 (For HSIL/cancer)
HPV L2/L1 5600 and 5609 (CpGs) Cervical cancer 80 (For severe dyskaryosis) 86.7 (For severe dyskaryosis) (130)
SOX1 Cervical cancer 68 (For SCC) 26 (For HSIL/SCC) 94 (For SCC) 97 (For HSIL/SCC) (131)
PAX1 86 (For SCC) 54 (For HSIL/SCC) 82 (For SCC) 99 (For HSIL/SCC)
LMX1A 36 (For SCC) 22 (For HSIL/SCC) 88 (For SCC) 90 (For HSIL/SCC)
NKX6-1 64 (For SCC) 58 (For HSIL/SCC) 59 (For SCC) 67 (For HSIL/SCC)
WT1 77 (For SCC) 52 (For HSIL/SCC) 74 (For SCC) 84 (For HSIL/SCC)
CDH13, HSPA2, MLH1, RASSF1A,
and SOCS2
Endometrial cancer 100 80 (132)
miRNA
miR-205 Ovarian cancer 30.1 94.2 (133)
Let-7f 66.9 84.2
miR-205/Let-7f 62.4 92.9
77.8 (For stage I) 90.0 (For stage I)
CDH13, cadherin 13; CIN, cervical intraepithelial neoplasia; DAPK1, death-associated protein kinase 1; HPV, human papilloma virus; HSIL, high-grade squamous
intraepithelial lesions; HSPA2, heat shock 70 kDa protein 2; ICC, invasive cervical cancer; LMX1A, LIM homeobox transcription factor 1 alpha; miRNA, microRNA;
MLH1, mutL homolog 1; NKX6-1, NK6 homeobox 1; PAX1, paired box 1; RASSF1A, RAS association family 1; RARB, retinoic acid receptor beta; SCC, squamous cell
carcinoma; SOCS2, suppressor of cytokine signaling 2; SOX1, SRY-box 1; TWIST1, twist basic helix–loop–helix transcription factor 1; WT1, Wilms tumor 1.
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thrombospondin 1 (TSP-1), MGMT, and others, are inactivated
through promoter region DNA hypermethylation. Among these
genes,TSP-1 shows a potential prognostic role in VSCC recurrence
(137), and TP73 displays features that may serve as therapeutic
biomarkers in vulvar cancer (138). DNA hypomethylation pat-
terns may also be used as potential prognostic markers in several
cancers. DNA demethylation in the promoter region of urokinase
(139) and P-cadherin (140) increases the expression levels of both
genes and is correlated with clinical outcomes in invasive breast
cancer. DNA hypomethylation of certain repetitive sequences in
HCC is also associated with disease recurrence, suggesting the
diagnostic value of DNA hypomethylation (141). Pattamadilok
et al. (142) have reported that decreased LINE-1 DNA methy-
lation levels are related to advanced tumor grade, and patients
with downregulated LINE-1 DNA methylation levels have poor
overall survival. DNA hypomethylation of LINE-1 is an impor-
tant process in ovarian cancer carcinogenesis and has potential for
use as a prognostic marker in epithelial ovarian cancers. A recent
work (133) has suggested that plasma miRNAs have the poten-
tial to be diagnostic and prognostic biomarkers in ovarian cancer.
They found increased miR-205 and decreased let-7f levels in the
plasma of early stage epithelial ovarian cancer patients and report
that the combination of miR-205/let-7f is a powerful diagnostic
factor in early-stage epithelial ovarian cancer. Because obtaining
plasma from patients is convenient, miRNA has great potential to
be a novel non-invasive biomarker.
EPIGENETIC THERAPY IN GYNECOLOGIC CANCER
The most fundamental way to cure cancer is to restore abnor-
mal gene expression regulation systems. Epigenetic therapy may,
therefore, occupy a significant portion of cancer treatment. Epige-
netic therapy has been studied in diverse ways since the discovery
of aberrant epigenetic regulation in cancer. A typical epigenetic
drug is azacitidine, which is a chemical analog of cytosine nucleo-
sides (143). This drug is mainly indicated to treat myelodysplastic
syndrome, and it has received approval by the U.S. Food and
Drug Administration. Because epigenetic studies of cancer have
focused on the repression of TSGs through repressive epigenetic
mechanisms, many epigenetic drugs (e.g., 5-aza-CdR) also tar-
get epigenetic reactive functions. However, in cancers caused by
aberrant overexpression of oncogenes or CPGs through epigenetic
derepression mechanisms, suppression of abnormal epigenetic
derepression is a therapeutic target. As described above, many
studies of epigenetic derepression in gynecologic cancers have been
published recently. Therefore, new drugs that repress the expres-
sion of oncogenes or CPGs through epigenetic mechanisms might
provide novel therapeutic approaches for treating specific cancers.
For example, proto-oncogene BCL6 is reportedly repressed by the
epigenetic drugs 5-aza-CdR and 4-phenylbutyric acid, which make
chromatin structure more flexible to activate gene expression. In
these cases, increased miR-127 facilitates the degradation of its tar-
get gene BCL6 through canonical RNA interference mechanisms,
downregulating BCL6 expression (144).
The results of these studies are evidence of complex epige-
netic regulation systems and suggest the potential use of epigenetic
drugs that repress the expression of proto-oncogenes in the treat-
ment of cancer. Another well-known TSmiRNA, the let-7 family, is
also a potential candidate for cancer therapy. Wang et al. (145) have
demonstrated that let-7i strongly lowers the expression of KRAS
and HMGA2 in lung cancer cells and shows anti-cancer activities
through inhibition of cell growth and migration. Because a single
TSmiRNA can repress the expression of multiple CPGs, TSmiRNA
therapy may have potent anti-cancer activity. Research on cancer
therapy targeting epigenetic derepression remains to be completed,
but the number of studies showing aberrant epigenetic derepres-
sion mechanisms in cancer development is rapidly increasing.
Novel epigenetic drugs targeting derepressed oncogenes will be
central in epigenetic cancer therapies.
CONCLUSION
Abnormal expression of diverse genes involved in cancer-
related properties such as cell growth or differentiation is a
main causal factor in cancer development (146). Some critical
genetic/epigenetic mutations can transform normal cell to cancer
cell, and accumulation of cancer-related genes abnormal expres-
sion increases its severity. Epigenetic mechanisms are primary
sources of this aberrant gene expression. Growing evidences have
shown that epigenetic derepression mechanisms including DNA
demethylation, gain of active histone modifications, TSmiRNA
downregulation, oncogenic alternative splicing and hypomethy-
lation of repeated sequences play critical roles in cancer devel-
opment. These aberrant epigenetic changes occur in all stage of
cancer, from early stages of carcinogenesis to cancer metastasis
and resistance to therapy. As shown in above, a lot of stud-
ies have found that various epigenetic derepression mechanisms
contribute progression of gynecologic cancers, and can be used
as diagnostic, prognostic marker for gynecologic cancer therapy.
Actually, these multiple epigenetic mechanisms work together to
regulate gene expression system. Therefore, integrated analysis of
diverse epigenetic factors is important in understanding the epige-
netic derepression mechanism of oncogene or CPG expression in
gynecologic cancer. Compared to the researches of TSGs epigenetic
inactivation, epigenetic activation of CAGEs are not studied well.
So, additional research on the activation of oncogenes or CPGs via
epigenetic depression is essential for a comprehensive understand-
ing of the epigenetic mechanisms of gynecologic cancer. Moreover,
studies of epigenetic derepression will provide insight into cancer
development mechanisms and improved therapeutic approaches
for gynecologic cancers.
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